Comparison of 60 and 80 mg/m of daunorubicin in induction therapy of acute myeloid leukaemia.

Vaezi M, Bahar B, Mousavi A, Yaghmai M, Kasaeian A, Souri M, Jahani M, Alimoghaddam K, Ghavamzadeh A
Hematol Oncol. 2017 35 (1): 101-105

PMID: 26386260 · DOI:10.1002/hon.2236

MeSH Terms (24)

Adolescent Adult Antibiotics, Antineoplastic Chromosome Aberrations Cytarabine Daunorubicin Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Febrile Neutropenia Female Follow-Up Studies Humans Kaplan-Meier Estimate Leukemia, Myeloid, Acute Male Middle Aged Mycoses Neutropenia Prevalence Prospective Studies Remission Induction Treatment Outcome Young Adult

Connections (1)

This publication is referenced by other Labnodes entities: